培美曲塞联合化疗治疗复发性非小细胞肺癌临床观察  

Clinical Observation of Pemetrexed Combined with Chemotherapy in the Treatment of Recurrent Non-small Cell Lung Cancer

作　　者：张建华[1] 乐兆喜 严晓春[1] 吴云[1] 

机构地区：[1]淮安市肿瘤医院肿瘤内科十病区,江苏淮安223200

出　　处：《肿瘤基础与临床》2013年第1期21-23,共3页journal of basic and clinical oncology

摘　　要：目的观察培美曲塞联合化疗治疗复发性非小细胞肺癌(NSCLC)的疗效及毒副反应。方法 32例复发性晚期NSCLC患者接受培美曲塞联合化疗方案治疗:培美曲塞500 mg.m-2,第1天,静脉滴注;顺铂20 mg.m-2,第1～4天,静脉滴注;每3周重复;或培美曲塞500 mg.m-2第1天,静脉滴注;奥沙利铂65mg.m-2第1、8天,静脉滴注,每3周重复。2周期后评价疗效及毒副反应。结果 32例中无CR病例,PR7例,SD 15例,PD 10例,有效率21.9%,临床获益率68.8%。主要毒副反应为白细胞减少、皮疹和胃肠道反应。结论培美曲塞联合化疗方案治疗复发性NSCLC疗效确切,对腺癌更具有治疗优势。毒副反应发生率低,耐受性较好。Objective To observe the curative effect and toxicities of pemetrexed combined with chemotherapy inthe treatment of the patients with recurrent non-small cell lung cancer （ NSCLC ）. Methods Thirty-two patients with recurrent NSCLC received the pemetrexed combined with chemotherapy： pemetrexed （500 mg · m^-1, d1, intravenous drip） plus cisplatin （ 20 mg · m - 2, d1-4, intravenous drip） or pemetrexed （ 500 mg· m- 1, d1, intravenous drip） plus oxaliplatin （65 mg · m-2 ,d1.8 ,intravenous drip）,3 weeks was 1 cycle. After 2 cycles of chemotherapy, the curative effect and toxicities were evaluated. Results Of the 32 patients, no CR was observed,PR in the 7 patients, SD in the 15 cases, PD in the 10 patients, the effective rate was 21.9%, the clinical benefit rate was 68.8%. The main toxicities were leukocytopenia,rash and gastrointestinal reaction. Conclusion Pemetrexed combined with chemotherapy is effective and safe in the treatment of the patients with recurrent NSCLC.

关 键 词：培美曲塞 顺铂 奥沙利铂 复发 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]